Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which GERD syrup works best? new study pits alginate against sucralfate

NCT ID NCT07310927

Symptom relief Sponsor: CMH Lahore Medical College and Institute of Dentistry Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study tested whether alginate (Gaviscon) or sucralfate (Ulsanic) provides better symptom relief for people with GERD who are already taking acid-reducing medication (PPIs). 140 adults with frequent severe heartburn took one of the two syrups before meals. Researchers measured symptom severity and quality of life using questionnaires. The goal was to see which add-on treatment works best and is easier to tolerate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Alginate (Gaviscon) and Sucralfate (Ulsanic)
What this could lead to
If this works, it could show that adding alginate or sucralfate to standard PPI therapy provides better symptom relief for people with GERD.
What could go wrong
This is a completed Phase 2/3 trial with 140 participants, but it compares two existing drugs, so it is not a breakthrough. Results may not apply to everyone with GERD, especially those with certain health conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

140 people

The number who actually took part.

Started

Apr 2025

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients having symptoms of severe GERD for more than 3 times /week Exclusion Criteria: 1. Patients with preexisting cardiovascular disorders 2. Patients with chronic kidney or liver diseases 3. Patients with gross abnormalities on upper GI endoscopies e.g.; ulcers, tumors or those with history of upper GI surgery 4. Pregnant and breast feeding 5. Absence of Erosive esophagitis 6. Patients with peptic esophageal ulcers 7. PPI use within 4 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GERD

Contacts and locations

Locations

  • Cmh Lahore

    Lahore, Punjab Province, 54180, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.